Year: 2022
Type: review
Abstract: -synuclein as a key pathogenic protein in this disease as well as in dementia with Lewy bodies, making it of leading therapeutic interest. This review discusses the various approaches being investigated and progress made to date toward discovering and developing therapeutics that would slow and stop progression of these disabling diseases.
Source: Pharmacological Reviews
Institution: Rutgers Health
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
Awards: G1631767658, G3068449229, RNA Targeted Drug Discovery and Development for Parkinson Disease, G4141186792, G4837789887, Developing Novel RNA-Based Therapeutics for Parkinson's Disease, PP2A Dysregulation in the Pathogenesis of alpha-Synucleinopathies, RNA Targeted Drug Discovery and Development for Parkinson Disease, Role of Transglutaminase 2 in Synucleinopathies, Synergistic Neuroprotective Mechanisms of Coffee Components in Parkinson's Diseas, G8733259384, Developing Novel RNA-Based Therapeutics for Parkinson's Disease, G9000147596, G9000250933
OpenAlex ID: W4206464678
